Medtronic InterStim SureScan MRI notice: lead and extension pairing errors under scrutiny

What the notice says

The Dutch healthcare inspectorate IGJ has published a manufacturer field safety notice (FSN) from Medtronic dated 5 October 2026. It concerns incompatible lead and percutaneous extension pairings in the company's InterStim SureScan MRI system. According to the record, the notice cites 15 complaints.

Our record logs the IGJ listing on 1 November, almost four weeks after the date on the notice. That gap is a reminder that a manufacturer's notice date and a regulator's publication date are different things. Customers may have received the communication well before it appeared on a public register, and teams that monitor only regulator sites may be working from older information than they assume.

What is not yet known

The summary we hold does not describe the clinical consequences of an incompatible pairing. It does not say which lead or extension models are involved, how many units are affected, or what Medtronic asks users to do. It also does not say whether the problem lies in labelling, ordering, product design or clinical selection. The 15 complaints come without a denominator, such as units sold or implanted, so they cannot be read as a failure rate.

Readers should therefore go to the FSN itself and not rely on the headline. In particular, the system's "MRI" name should not be taken as evidence of an MRI-related hazard, because the record does not say that. Until the full text has been read, treat the scope, the risk and the required actions as open questions.

Why the pairing problem matters for quality teams

The wording points to a selection problem: the wrong combination of components being chosen or used together. Where the system relies on matching a lead to an extension, compatibility depends on information reaching the person who makes the choice. That means labelling, catalogue and ordering data, instructions for use and training all play a part.

For a hospital or distributor, the practical questions are whether stock-keeping and procurement records make the compatible combinations clear, and whether theatre or implant teams check compatibility at the point of use. For a manufacturer, a complaint cluster of this kind normally prompts a look at usability, labelling and complaint trending, though the notice itself will show what Medtronic actually concluded.

Fifteen complaints is a small number in absolute terms. The fact that it was enough to produce a published FSN shows how sharply a configuration error can be treated when it involves implantable device components.

The same week: other signals with a common thread

Several other records from the past days show how often a manufacturing or presentation detail turns into a field action.

Baxter Holding B.V. reported incomplete aluminium crimping on Caelyx 50 mg/25 ml single-dose vials, which can leave a vial open once the cap is removed. BfArM published the Rote-Hand-Brief, and Slovakia's ŠÚKL released a DHPC citing possible loss of sterility and unintended occupational exposure when the protective cover is removed. That is one defect with two consequences, one for product quality and one for staff safety.

Siemens Healthineers flagged a single lot of its tox Serum Tricyclic Antidepressant Calibrator Control containing more sodium azide than specified. The company reports no effect on performance, yet the lot is still outside specification and has been communicated. In Canada, Health Canada recalled one lot of Equate Ultra Strength Antacid Assorted Fruits chewable tablets over possible stainless steel shavings, classed Type II.

BfArM also listed FSNs from Philips (Azurion image-guided therapy system) and Intersurgical (Smoothbore Breathing System). In both cases the substance sits only in the manufacturer's attached advisory, so the public listing alone tells a reader very little.

Who is affected and what to watch

Hospital device-vigilance officers, biomedical engineering and procurement teams, distributors, and any clinical unit using the InterStim SureScan MRI system should locate the full FSN and confirm whether they hold affected configurations. Manufacturers of multi-component devices will recognise the underlying issue: compatibility must be obvious to the user, not just correct on paper.

Watch for four things. First, whether the full notice names specific models or lots. Second, whether other EU regulators republish it, as happened with Caelyx. Third, whether Medtronic issues further communications or updated instructions. Fourth, whether regulators say anything about the cause. None of these is established in the records we hold.